HCW Biologics Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
HCW Biologics Inc. (HCWB) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.22 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-14
- HCW Biologics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.22K, a 99.56% decline year-over-year.
- HCW Biologics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $10.02K, a 96.37% decline year-over-year.
- HCW Biologics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $205.49K, a 11.59% decline year-over-year.
- HCW Biologics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $278.31K, a 16.05% increase year-over-year.
- HCW Biologics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $768.62K, a 23.82% decline from fiscal 2024.
- HCW Biologics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $1.01M, a 0.52% increase from fiscal 2023.
- HCW Biologics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $1.00M, a 10.39% decline from fiscal 2022.
- HCW Biologics Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $1.12M, a 210.32% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.22K 10-Q · filed 2026-08-14 | $11.24K derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2026-03-31 | $10.02K 10-Q/A · filed 2026-08-14 | |||
| 2025-12-31 | $768.62K 10-K · filed 2026-03-31 | |||
| 2025-09-30 | $205.49K 10-Q · filed 2025-11-14 | $483.80K derived: sum of 2 quarters · filed 2026-08-14 | $759.44K derived: sum of 3 quarters · filed 2026-08-14 | |
| 2025-06-30 | $278.31K 10-Q · filed 2026-08-14 | $553.95K derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $275.64K 10-Q/A · filed 2026-08-14 | |||
| 2024-12-31 | $1.01M 10-K · filed 2026-03-31 | |||
| 2024-09-30 | $232.43K 10-Q · filed 2025-11-14 | $472.25K derived: sum of 2 quarters · filed 2025-11-14 | $716.94K derived: sum of 3 quarters · filed 2025-11-14 | |
| 2024-06-30 | $239.82K 10-Q · filed 2025-11-14 | $484.51K derived: sum of 2 quarters · filed 2025-11-14 | ||
| 2024-03-31 | $244.69K 10-Q · filed 2025-11-14 | |||
| 2023-12-31 | $1.00M 10-K · filed 2025-03-28 | |||
| 2023-09-30 | $219.85K 10-Q · filed 2024-11-14 | $483.27K derived: sum of 2 quarters · filed 2024-11-14 | $742.48K derived: sum of 3 quarters · filed 2024-11-14 | |
| 2023-06-30 | $263.42K 10-Q · filed 2024-11-14 | $522.63K derived: sum of 2 quarters · filed 2024-11-14 | ||
| 2023-03-31 | $259.21K 10-Q · filed 2024-11-14 | |||
| 2022-12-31 | $1.12M 10-K/A · filed 2024-05-15 | |||
| 2022-09-30 | $302.32K 10-Q · filed 2023-11-14 | $573.65K derived: sum of 2 quarters · filed 2023-11-14 | $834.00K derived: sum of 3 quarters · filed 2023-11-14 | |
| 2022-06-30 | $271.33K 10-Q · filed 2023-11-14 | $531.68K derived: sum of 2 quarters · filed 2023-11-14 | ||
| 2022-03-31 | $260.35K 10-Q · filed 2023-11-14 | |||
| 2021-12-31 | $360.98K 10-K · filed 2023-03-28 | |||
| 2021-09-30 | $1.66K 10-Q · filed 2022-11-07 | $11.24K derived: sum of 2 quarters · filed 2022-11-07 | $11.88K derived: sum of 3 quarters · filed 2022-11-07 | |
| 2021-06-30 | $9.58K 10-Q · filed 2022-11-07 | $10.22K derived: sum of 2 quarters · filed 2022-11-07 | ||
| 2021-03-31 | $641.00 10-Q · filed 2022-11-07 | |||
| 2020-12-31 | $21.87K 10-K · filed 2022-03-29 | |||
| 2020-09-30 | $1.75K 10-Q · filed 2021-11-12 | $11.27K derived: sum of 2 quarters · filed 2021-11-12 | $11.34K derived: sum of 3 quarters · filed 2021-11-12 | |
| 2020-06-30 | $9.52K 10-Q · filed 2021-11-12 | $9.59K derived: sum of 2 quarters · filed 2021-11-12 | ||
| 2020-03-31 | $76.00 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |